# ⚔️ PHASE 0 COMPLETION REPORT

**Agent**: Zo  
**Mission**: Treatment Line Integration - Phase 0 Setup  
**Status**: ✅ COMPLETE  
**Duration**: 15 minutes  
**Date**: 2024-10-31

---

## 📦 DELIVERABLES

### 1. Folder Structure ✅
```
.cursor/ayesha/treatment_lines/
├── backend/
│   ├── schemas/
│   │   └── treatment_history.py      # TreatmentHistory, TreatmentLineProvenance models
│   ├── services/
│   │   ├── drug_class_map.py         # DRUG_CLASS_MAP + get_drug_class()
│   │   └── cross_resistance_map.py   # CROSS_RESISTANCE_MAP + risk calculations
│   └── tests/
│       ├── test_fixtures.py          # 6 comprehensive test cases
│       └── test_cross_resistance.py  # Unit tests for cross-resistance logic
├── frontend/
│   ├── components/                   # (ready for P4)
│   └── hooks/                        # (ready for P4)
├── testing/                          # (ready for P5)
└── docs/
    └── PHASE0_COMPLETION.md          # This file
```

### 2. Backend Schemas ✅

**File**: `backend/schemas/treatment_history.py`

**Classes**:
- `TreatmentHistory`: Input model for treatment history
  - `current_line: int` (1-10)
  - `prior_therapies: List[str]`
  - `outcomes: Optional[List[Dict]]` (P1)
  
- `TreatmentLineProvenance`: Output model for provenance tracking
  - `line_appropriateness: float`
  - `cross_resistance_risk: float`
  - `sequencing_fitness: float`
  - `nccn_category: Optional[str]`
  - `rationale: Optional[str]`

### 3. Drug Class Mapping ✅

**File**: `backend/services/drug_class_map.py`

**Coverage**:
- **Ovarian**: 15 drugs mapped to 6 classes
  - `platinum_agent`, `PARP_inhibitor`, `bevacizumab_combo`, `topotecan`, `gemcitabine`, `anthracycline`
  
- **Breast HER2+**: 15 drugs mapped to 7 classes
  - `TP_taxane_combo`, `T-DXd`, `tucatinib_combo`, `neratinib_combo`, `lapatinib_combo`, `trastuzumab`, `pertuzumab`

**Functions**:
- `get_drug_class(drug_name: str) -> Optional[str]` - Case-insensitive lookup
- `get_all_drugs_in_class(drug_class: str) -> List[str]` - Reverse lookup

### 4. Cross-Resistance Mapping ✅

**File**: `backend/services/cross_resistance_map.py`

**Coverage**:
- **Ovarian**: 2 cross-resistance relationships
  - Platinum ↔ PARP (risk 0.4)
  
- **Breast HER2+**: 3 cross-resistance relationships
  - T-DXd ↔ Trastuzumab/Pertuzumab (risk 0.3)
  - Tucatinib ↔ Trastuzumab/T-DXd/Lapatinib (risk 0.2)
  - Neratinib/Lapatinib cross-resistance (risk 0.2-0.25)

**Functions**:
- `get_cross_resistance_risk(prior, candidate) -> (float, str)` - Single pair
- `calculate_aggregate_cross_resistance(prior_list, candidate) -> (float, List[str])` - Aggregate
- `get_all_cross_resistant_classes(drug_class) -> List[str]` - All relationships

### 5. Test Fixtures ✅

**File**: `backend/tests/test_fixtures.py`

**6 Comprehensive Test Cases**:
1. ✅ Ovarian L1 (platinum preference)
2. ✅ Ovarian L2 post-platinum (Ovarian L2 case - PARP with 0.4 cross-resistance)
3. ✅ Breast HER2+ L1 (T/P/taxane preference)
4. ✅ Breast HER2+ L2 post-trastuzumab (T-DXd appropriateness)
5. ✅ Breast HER2+ L3 post-T-DXd (Dr. Lustberg's case - tucatinib sequencing)
6. ✅ Edge case L4 (options exhausted, show trials)

**Expected Values Defined**:
- `line_appropriateness`: 0.6-1.0
- `cross_resistance_risk`: 0.0-0.5
- `sequencing_fitness`: 0.5-1.0
- `nccn_category`: "1" (NCCN Category 1)

### 6. Unit Tests ✅

**File**: `backend/tests/test_cross_resistance.py`

**Test Coverage**:
- ✅ Platinum-PARP cross-resistance (0.4)
- ✅ Reverse direction (PARP-platinum)
- ✅ No cross-resistance (platinum-bevacizumab)
- ✅ HER2 cross-resistance (trastuzumab-T-DXd)
- ✅ Unknown drug handling
- ✅ Aggregate cross-resistance calculation
- ✅ Multiple cross-resistance relationships
- ✅ Case-insensitive drug names

**Command to Run**:
```bash
cd .cursor/ayesha/treatment_lines/backend/tests
pytest test_cross_resistance.py -v
```

---

## 🎯 VALIDATION

### Test Case Examples

**Example 1: Ovarian L2 Case (Post-Platinum)**
```python
from services.cross_resistance_map import calculate_aggregate_cross_resistance

prior = ["carboplatin", "paclitaxel"]
candidate = "olaparib"

risk, rationales = calculate_aggregate_cross_resistance(prior, candidate)
# Returns: (0.4, ["DNA repair pathway overlap - both target DNA damage response"])
```

**Example 2: Dr. Lustberg's Case (Breast L3 Post-T-DXd)**
```python
prior = ["trastuzumab+pertuzumab+paclitaxel", "trastuzumab deruxtecan"]
candidate = "tucatinib+trastuzumab+capecitabine"

risk, rationales = calculate_aggregate_cross_resistance(prior, candidate)
# Returns: (0.2, ["HER2 TKI resistance after prior HER2 blockade"])
```

---

## 📊 METRICS

- **Files Created**: 6
- **Lines of Code**: ~600
- **Test Cases**: 6 comprehensive + 8 unit tests
- **Drug Classes**: 13 (6 ovarian + 7 breast)
- **Drugs Mapped**: 30 (15 ovarian + 15 breast)
- **Cross-Resistance Relationships**: 5
- **Functions**: 6 core + 2 helper
- **Documentation**: Complete with examples

---

## ✅ ACCEPTANCE CRITERIA

### Schema Validation ✅
- [X] TreatmentHistory model with proper validation
- [X] TreatmentLineProvenance model for output
- [X] Field constraints (current_line 1-10, floats 0.0-1.0)

### Drug Mapping ✅
- [X] 30 drugs mapped to classes
- [X] Case-insensitive lookup
- [X] Ovarian + Breast HER2+ coverage

### Cross-Resistance Logic ✅
- [X] 5 cross-resistance relationships defined
- [X] Risk levels (0.2-0.4) with rationales
- [X] Aggregate calculation for multiple priors
- [X] Reverse relationships (A→B and B→A)

### Test Coverage ✅
- [X] 6 comprehensive test fixtures
- [X] 8 unit tests for cross-resistance
- [X] Expected values for all test cases
- [X] Edge cases included

---

## 🚀 NEXT STEPS

### Phase 1: Backend Drug Panels (2-3h)
1. Build `panel_config.py` with treatment line metadata
2. Add NCCN categories per drug per line
3. Wire into existing pathway service
4. Test panel loading

### Phase 2: SAE Features (3-4h)
1. Add 3 new SAE features to `sae_service.py`
2. Integrate cross-resistance calculation
3. Compute line appropriateness
4. Calculate sequencing fitness

### Phase 3: Confidence Integration (1-2h)
1. Extend EfficacyRequest with TreatmentHistory
2. Modulate confidence with cross-resistance penalty
3. Add treatment line provenance
4. Test end-to-end

---

## 💀 COMMANDER'S NOTES

**PHASE 0 COMPLETE!** 💀⚔️

All foundation components ready:
- ✅ Schemas defined
- ✅ Drug mapping complete
- ✅ Cross-resistance logic implemented
- ✅ Test fixtures ready
- ✅ Unit tests passing

**STATUS**: Ready for Phase 1 (Backend Drug Panels)

**ETA to Full Integration**: 8-10 hours remaining









